Bayer paid approximately $2.04 billion to settle roughly 10,300 blood clot injury claims related to its Yaz and Yasmin birth control pills, with individual payouts averaging between $212,000 and $220,000 per case. These settlements, reached over several years of litigation, resolved claims that the drospirenone-containing contraceptives caused deep vein thrombosis, pulmonary embolism, strokes, and heart attacks. In one notable round of settlements in 2012, Bayer resolved 500 lawsuits at roughly $220,000 each, totaling $110 million in a single batch.
Beyond blood clot claims, Bayer also paid $56.9 million to settle approximately 1,200 arterial blood clot claims involving strokes and heart attacks, and another $21.5 million to resolve around 7,200 gallbladder injury claims. Over 19,000 total lawsuits have been resolved. This article breaks down the settlement amounts by category, examines what determined individual payouts, explains the FDA risk data that fueled the litigation, and covers the current status of remaining claims in 2026.
Table of Contents
- How Much Did Yaz Blood Clot Lawsuit Settlements Pay Per Case?
- The Full Scope of Bayer’s Yaz Settlement Payouts
- FDA Warnings and the Science Behind the Lawsuits
- Filing a Yaz Lawsuit in 2026 — Is It Still Possible?
- What Bayer Admitted — and What It Didn’t
- How Yaz Settlements Compare to Other Pharmaceutical Mass Torts
- Lessons From the Yaz Litigation and What Comes Next
- Conclusion
- Frequently Asked Questions
How Much Did Yaz Blood Clot Lawsuit Settlements Pay Per Case?
The per-case settlement amounts in the Yaz litigation varied, but the numbers clustered around a consistent range. In a separate round of negotiations, Bayer resolved approximately 1,900 cases at an average of $212,000 per case. In 2012, another batch of 500 lawsuits settled at roughly $220,000 each. Bayer also paid $400 million in one year alone to settle about 2,000 blood clot claims, which works out to approximately $200,000 per case in that tranche. These averages mask significant variation.
Cases involving permanent injury, prolonged hospitalization, or young plaintiffs with decades of lost quality of life likely commanded higher payouts, while cases with shorter recovery periods or pre-existing risk factors may have settled for less. Mass tort settlements rarely pay everyone the same amount. Instead, claims are typically evaluated on a grid that accounts for injury severity, medical documentation, age, and economic losses. It is worth noting that these are gross settlement figures. After attorney fees, which typically run 33 to 40 percent in contingency arrangements, plus litigation costs, the net amount received by individual plaintiffs was substantially lower. A $220,000 gross settlement could translate to roughly $130,000 to $145,000 in the plaintiff’s pocket after legal fees and expenses.
The Full Scope of Bayer’s Yaz Settlement Payouts
By January 2016, Bayer had paid $2.04 billion to resolve approximately 10,300 blood clot injury claims, including cases involving deep vein thrombosis and pulmonary embolism. The pace of settlements accelerated over time. By October 2013, at least $1.4 billion had been paid across 6,700 lawsuits, meaning Bayer paid roughly another $640 million over the following two years to resolve the remaining cases. The arterial blood clot claims, which involved more serious injuries like strokes and heart attacks, were settled separately.
Bayer agreed to pay $56.9 million to resolve approximately 1,200 of these claims. The per-case average for arterial claims was notably lower at roughly $47,400, which may reflect the difficulty of proving causation for strokes and heart attacks, conditions that have multiple potential causes beyond oral contraceptive use. However, if a plaintiff had strong evidence tying an arterial event directly to drospirenone use, particularly in a young, otherwise healthy woman with no cardiovascular risk factors, the individual payout could have been considerably higher than that average. Averages in mass tort settlements are often pulled down by weaker claims that settle for nominal amounts rather than risk dismissal at trial.
FDA Warnings and the Science Behind the Lawsuits
The legal foundation for the Yaz litigation rested heavily on FDA risk data about drospirenone, the progestin used in Yaz, Yasmin, Beyaz, and their generics like Ocella. In 2012, the FDA updated labels for all drospirenone-containing pills to warn of increased blood clot risk. An FDA-funded study found that these pills carry a 1.5 to 3 times increased risk of blood clots compared to pills containing levonorgestrel, an older progestin. In concrete terms, the blood clot risk with drospirenone pills was approximately 10 in 10,000 women per year, compared to 6 in 10,000 for other progestins.
While both numbers are small in absolute terms, the relative increase was significant enough that the FDA required labeling changes. For context, that means for every 10,000 women taking drospirenone pills for a year, roughly 4 additional women would develop a blood clot compared to those on older formulations. Plaintiffs’ attorneys argued that Bayer knew or should have known about these elevated risks and marketed Yaz aggressively without adequate disclosure. Bayer’s own marketing had positioned Yaz as a lifestyle drug that could treat acne and premenstrual symptoms, which critics said encouraged use by women who might have chosen a safer contraceptive if fully informed of the comparative risks. The gap between Bayer’s marketing and the FDA’s eventual risk assessment became a central theme of the litigation.
Filing a Yaz Lawsuit in 2026 — Is It Still Possible?
The federal multidistrict litigation for Yaz claims closed in January 2019, and the vast majority of U.S. claims have been resolved. For most American women who experienced blood clot injuries from Yaz or Yasmin, the window to file has long passed. State statutes of limitations for pharmaceutical injury claims typically range from 2 to 6 years from the date of injury discovery, meaning most potential claims from the drug’s peak usage period in the late 2000s and early 2010s have expired. There is an important distinction between when an injury occurred and when it was discovered.
The discovery rule, recognized in most states, starts the statute of limitations clock when a plaintiff knew or reasonably should have known that her injury was connected to the medication. A woman who suffered a pulmonary embolism in 2010 but only learned in 2024 that her specific birth control pill was linked to clotting disorders might argue for a later start date, though this becomes increasingly difficult to establish as public awareness of the Yaz risks has grown over the past decade. In Canada, proceedings remain active. A Canadian class action involving Yaz and Yasmin is still being adjudicated, with Saskatchewan class members given until January 15, 2026, to file objections and a hearing rescheduled to February 11, 2026. Canadian plaintiffs may still have avenues for recovery that are no longer available in the United States.
What Bayer Admitted — and What It Didn’t
A critical detail that often gets overlooked in coverage of the Yaz settlements is that Bayer resolved all claims without admission of wrongdoing or liability. This is standard practice in mass tort settlements, but it carries real consequences. It means there is no legal precedent establishing that Yaz caused any particular plaintiff’s blood clot, no court finding of negligence, and no binding determination that Bayer’s marketing was misleading. Bayer VP Steven Immergut stated the company agreed to settlements “to avoid the cost and distraction of litigation” and to refocus on patients.
From Bayer’s perspective, paying $2 billion was a business calculation. Continued litigation across thousands of individual cases would have consumed enormous legal resources, generated ongoing negative publicity, and carried the risk of occasional large jury verdicts that could have set unfavorable precedents. This no-admission posture means that Bayer can and does continue to sell drospirenone-containing contraceptives with updated labeling. Women currently taking these medications should not interpret the settlements as proof that the drugs are dangerous for all users, but rather as an acknowledgment that the risks were not adequately communicated during the earlier marketing period. The drugs remain FDA-approved and widely prescribed, though physicians are now expected to discuss the comparative blood clot risks with patients.
How Yaz Settlements Compare to Other Pharmaceutical Mass Torts
The $2.04 billion Yaz blood clot settlement ranks among the larger pharmaceutical mass tort resolutions, though it falls well short of the largest. For comparison, Merck paid $4.85 billion to settle Vioxx claims, and Johnson & Johnson has faced tens of billions in potential liability over talc-related claims.
The per-case average of $212,000 to $220,000 in the Yaz litigation was moderate by mass tort standards, reflecting the fact that while blood clots are serious, many plaintiffs recovered fully with treatment rather than suffering permanent disability or death. The Yaz litigation is frequently cited as a case study in how aggressive direct-to-consumer pharmaceutical marketing can create legal exposure. Bayer spent hundreds of millions advertising Yaz as a multi-benefit contraceptive, which broadened the user base far beyond what might have occurred with standard physician-directed marketing, ultimately increasing both the number of injuries and the number of resulting lawsuits.
Lessons From the Yaz Litigation and What Comes Next
The Yaz settlement wave is essentially over in the United States, but its impact continues to shape pharmaceutical litigation. The case established practical benchmarks for how blood clot injury claims against contraceptive manufacturers get valued and resolved. It also reinforced the importance of the discovery rule in pharmaceutical cases, as many plaintiffs filed years after their injuries when the connection to drospirenone became more widely publicized.
Looking ahead, the Canadian proceedings will be among the last major Yaz-related legal actions to conclude. For women in the U.S. who believe they were injured by Yaz or a related drospirenone contraceptive, the realistic path forward is narrow but not necessarily closed. Consulting with a pharmaceutical injury attorney about state-specific statute of limitations rules remains the only way to determine whether an individual claim is still viable.
Conclusion
Bayer’s $2.04 billion in Yaz blood clot settlements resolved over 10,300 claims at an average of $212,000 to $220,000 per case, making it one of the more significant pharmaceutical mass torts of the past two decades. Additional settlements addressed arterial blood clot injuries ($56.9 million for 1,200 claims) and gallbladder injuries ($21.5 million for 7,200 claims), bringing the total resolution well above $2 billion across more than 19,000 lawsuits. For anyone still considering whether they have a viable claim, time is the critical factor.
The federal MDL closed in 2019, and most U.S. statutes of limitations have likely expired for injuries that occurred during Yaz’s peak prescribing years. Canadian class actions remain active as of early 2026. Anyone who experienced a blood clot, stroke, or heart attack while taking a drospirenone-containing contraceptive should speak with an attorney experienced in pharmaceutical litigation to evaluate their specific situation, keeping in mind that Bayer settled all prior claims without admitting any wrongdoing.
Frequently Asked Questions
What was the average Yaz blood clot settlement amount?
Individual blood clot settlements averaged between $212,000 and $220,000 per case before attorney fees. In one 2012 batch, 500 cases settled at roughly $220,000 each. Net payouts to plaintiffs after legal fees were substantially lower.
How much did Bayer pay total in Yaz settlements?
Bayer paid approximately $2.04 billion to resolve about 10,300 blood clot claims, plus $56.9 million for arterial clot claims and $21.5 million for gallbladder injury claims. Over 19,000 total lawsuits were resolved.
Can I still file a Yaz lawsuit in 2026?
In the United States, most claims have been resolved and statutes of limitations have likely expired for injuries from Yaz’s peak prescribing years. Canadian class action proceedings remain active with hearings scheduled in early 2026. Consult an attorney to evaluate your specific situation based on your state’s discovery rule and limitation period.
Did Bayer admit that Yaz caused blood clots?
No. Bayer settled all claims without admission of wrongdoing or liability. The company stated it settled to avoid the cost and distraction of continued litigation. Yaz and other drospirenone-containing contraceptives remain FDA-approved and available by prescription.
What is the blood clot risk with Yaz compared to other birth control pills?
FDA-funded studies found drospirenone pills like Yaz carry a 1.5 to 3 times increased risk of blood clots compared to pills containing levonorgestrel. In absolute terms, the risk is approximately 10 in 10,000 women per year for drospirenone pills versus 6 in 10,000 for other progestins.
What types of injuries were covered in the Yaz settlements?
The primary settlements covered venous blood clot injuries including deep vein thrombosis and pulmonary embolism. Separate settlements addressed arterial blood clot injuries such as strokes and heart attacks, as well as gallbladder injuries.